جست‌وجوی استاد و پژوهشگر

Wendy A. Goodmanمشاهده پروفایل

استادیار

• Immunology
• Endocrinology
• Gastroenterology
• +۷ مورد دیگر

Wendy A. Goodman, PhD is an Assistant Professor in the Department of Pathology at the Case Western Reserve University School of Medicine . She is also a Member of the Immune Oncology Program at the Case Comprehensive Cancer Center. Her research focuses on the role of steroid hormones (e.g., estrogens, androgens, progesterone) in immune regulation, particularly in mucosal tissues (e.g., intestinal mucosa) and maternal-fetal interface tissues (e.g., decidua). She employs preclinical mouse models and primary human cells/tissues to study mechanisms underlying immune homeostasis, chronic inflammation, and autoimmunity. Dr. Goodman’s education includes a Bachelor of Arts in Biology (2001) and a PhD in Pathology/Immunology (2010), both from Case Western Reserve University. Her research interests emphasize non-classical roles of sex hormones in adaptive and innate immune responses, including T-cell differentiation, regulatory T cell function, and immune cell/epithelial crosstalk. She investigates how local environmental cues in the gut and pregnancy tissues shape protective vs. pathogenic immune responses. Her work is supported by significant grants including an NIH/NIDDK R01 (2021-2026) and the March of Dimes Ohio Collaborative (2020-current) . Notable awards include the Michael E. Lamm Teaching Award (2018) and multiple Best Abstract Awards at conferences like FASEB GI Summer Conference (2017) and Advances in IBD (2015). She collaborates with institutions like Cincinnati Children’s Medical Center on pregnancy-related immune studies. Dr. Goodman has advised numerous research projects but no formal students are listed. Her lab actively explores estrogen/progesterone crosstalk during pregnancy, hormonal control of myeloid cells, and mechanisms driving IBD sexual dimorphism. Professional memberships include the American Association of Immunologists, Crohn’s and Colitis Foundation, and American Gastroenterological Association.

• Regenerative Lung Engineering
• Cell-to-Cell Communication Networks
• Systems Biology
• +۵ مورد دیگر

Dr. Micha Sam Brickman Raredon is an Assistant Professor in the Department of Anesthesiology at Yale School of Medicine. He leads the Raredon Laboratory, focused on regenerative lung engineering, systems biology, and bioengineered tissues. His work integrates computational tools like NICHES and Connectome to study cell-cell communication networks in lung tissue. Dr. Raredon holds MD/PhD degrees from Yale and a master's from MIT in Materials Science. His research spans lung vascular networks, fibrosis mechanisms, and translational applications in regenerative medicine. He is affiliated with the Vascular Biology and Therapeutics Program, Program in Translational Biomedicine, and Yale Combined Program in the Biological and Biomedical Sciences (BBS). Education: MD/PhD Yale University (2022/2021), MS Yale Engineering (2020), MPhil Yale (2020), MS MIT (2014), BS Yale & Cambridge (2011). Research Interests: Engineering functional lung tissues, decoding lung microvascular niches, single-cell systems biology, and applying machine learning to tissue regeneration. Key projects include developing algorithms for cell-cell interaction analysis and engineering patient-specific lung tissues. Recent work addresses hypoxia-induced cardiopulmonary damage and fibrotic lung diseases. Publications reflect interdisciplinary focus on lung biology, vascular integrity, and computational methods. Awards include the Draper Fellowship for tissue fabrication innovation and the Yale MD/PhD Thesis Prize. His lab collaborates with leading figures like Drs. Kaminski, Niklason, and Medzhitov. Advising and Grants: Mentors students in translational research. Lab develops ventilator splitting systems for disaster medicine and bioengineered lung models. Active in NIH-funded projects on lung regeneration and fibrosis. Labs/Teams: Raredon Lab at Yale Vascular Biology Program. Collaborations span Yale's Systems Biology, Immunobiology, and Biomedical Engineering departments.

• Pathology
• Oncology
• Hepatology
• +۵ مورد دیگر

Dr. Wenyi Luo is an Assistant Professor of Pathology at Yale School of Medicine, specializing in Anatomic Pathology and GI Pathology. He holds roles such as Director of the Immunohistochemistry Lab and has previously served at the University of Oklahoma Health Sciences Center (OUHSC) as Assistant Professor and Surgical Pathology Rotation Director. His research focuses on liver and gastrointestinal pathology, oncology, and cellular mechanisms in diseases like hepatocellular carcinoma and pancreatic cancer. Education: MD from Peking University Health Science Center (2004), PhD in Genetics from University of Alabama Birmingham (2010), and postdoctoral training at UAB and MD Anderson Cancer Center. Board certified in Anatomic and Clinical Pathology. Research interests include cancer biology, necroptosis regulation, liver fibrosis, and therapeutic strategies for cholestasis and cholangiopathy. His work integrates molecular pathology with clinical outcomes, emphasizing translational applications. Notable contributions include studies on macrophage-cancer cell interactions in pancreatic cachexia and miRNA roles in adipogenesis. Collaborations span hepatology, oncology, and metabolic disorders. He has no listed awards but maintains an active publication record in high-impact journals like Cancer Cell and Gastroenterology . Labs/Teams: Involved in gastrointestinal and liver pathology research at Yale, contributing to interdisciplinary projects in cancer biology and liver disease mechanisms.

• Metabolic Disorders
• Hepatology
• Lipid Metabolism
• +۳ مورد دیگر

Dr. Yingdong Zhu is a Researcher in the Department of Pediatrics at Yale School of Medicine, Yale University. His work focuses on metabolic disorders, particularly nonalcoholic steatohepatitis (NASH), lipid metabolism, and atherosclerosis. He investigates molecular mechanisms involving transcription factors (e.g., ATF3, HNF4α), miRNAs, and retinoic acid receptors in metabolic and liver diseases. His research integrates hepatocyte, adipocyte, and macrophage biology to elucidate pathways linking metabolic dysfunction to cardiovascular and hepatic pathologies. Research interests include: Adipose-liver crosstalk in metabolic disorders Molecular regulation of NASH progression Role of retinoid signaling in atherosclerosis MicroRNA-mediated liver disease mechanisms No specific awards or grants are listed, but his contributions are evident through recent publications in metabolic and hepatic research. Advising roles or lab affiliations are not explicitly stated in available texts.

Diana Tavares Ferreiraمشاهده پروفایل

استادیار

• Cellular and molecular mechanisms of axonal integrity
• RNA transport and regulation
• Computational neuroscience
• +۳ مورد دیگر

Diana Tavares Ferreira is an Assistant Professor of Neuroscience at the University of Texas at Dallas (UTD) within the School of Behavioral and Brain Sciences . Her research focuses on understanding cellular and molecular mechanisms underlying axonal integrity in sensory neurons, particularly in neuropathies and neurodegenerative diseases. Education & Training: Postdoctoral Researcher in Neuroscience at UTD (2023) PhD in Neuroscience from the University of Sheffield, UK (2018) PharmD/MS in Pharmaceutical Sciences from the University of Coimbra, Portugal (2013) Research Interests: RNA transport dynamics in distal axons Role of non-coding RNAs (e.g., miRNAs) in sensory neuron function Computational integration of multi-omics data (single-cell, spatial transcriptomics) Mechanisms of axon-soma communication and axonal regeneration Her lab, the Axon Biology and Neuroinformatics Lab , combines experimental and computational approaches to decode how RNA regulation impacts nerve health and disease. Awards & Recognition: Peter J. Dyck Abstract Prize (2022) for diabetic neuropathy research Catalyst Studentship (2016) from the Higher Education Funding Council for England Grants & Funding: Data Core UTD PRECISION Pain Center (National Institute of Neurological Disorders and Stroke, 2022–2027) Dr. Ferreira is currently accepting graduate students and collaborates on projects involving spatial transcriptomics and translational control in chronic pain mechanisms.

• Inflammation and cancer
• Novel biomarkers for therapy efficacy and resistance
• Translational cancer research
• +۳ مورد دیگر

Prof. Klaus Schulze-Osthoff serves as Director and Chair of the Department of Molecular Medicine at the University of Tübingen, Germany, a position he has held since 2008. He maintains dual affiliation as a Research Fellow at the German Cancer Research Center (DKFZ) in Heidelberg since 2012 and acts as Spokesperson for the German Consortium for Translational Cancer Research (DKTK) at the Tübingen Partner Site. Previously, he directed the Institute of Molecular Medicine at the University of Düsseldorf (2001-2008) and served as Scientific Director of the Comprehensive Cancer Center in Tübingen (2009-2013). His research spans critical areas in molecular oncology with particular emphasis on: Inflammation and cancer interactions Novel biomarkers for therapy efficacy and resistance Translational cancer research bridging basic science and clinical applications Tumor immunology mechanisms Tumor cell senescence as antitumor mechanism Apoptosis and cell death pathways Analysis of his publication history reveals a clear research trajectory: foundational work (1990s) establishing mitochondrial roles in apoptosis and caspase functions, followed by therapeutic applications (2000s) demonstrating caspase relevance in cancer treatment, and recent focus (2010s) on tumor cell senescence mechanisms including the identification of novel NF-κB co-activators and development of the world's first senescence PET tracer for clinical imaging. His scientific leadership has been recognized through: Steering committee membership at the National Center for Tumor Diseases (2021-present) Board membership in Cluster of Excellence IFIT (2019-present) Multiple Research Grant Awards from German Cancer Aid Foundation (2016, 2005, 2002) German University Medical Innovation Award (2008) Scientific advisory roles for pharmaceutical companies including Pfizer His research program has successfully translated basic discoveries into clinical applications, particularly through biomarker development for therapy monitoring and the creation of novel imaging techniques. He has secured sustained funding from major German research foundations and maintains active collaborations across European research institutions. His laboratory continues to investigate molecular mechanisms of tumor cell senescence and apoptosis with direct relevance to cancer therapy development. The Molecular Medicine Department he leads at Tübingen focuses on translating fundamental discoveries into clinical applications, with particular expertise in developing diagnostic tools like the senescence PET tracer currently in patient trials, and identifying novel therapeutic targets in tumor immunology and cell death pathways.

• Cell Biology
• Molecular Biology
• Mitochondrial Biology
• +۵ مورد دیگر

Dr. Danilo Faccenda is a Lecturer in Biochemistry at the University of Hertfordshire's Department of Clinical, Pharmacological and Biological Sciences, within the School of Life and Medical Sciences. His research focuses on mitochondrial function's role in disease pathways, particularly cellular stress responses and mitochondria-nucleus communication in neurobiology and gastrointestinal inflammation. BSc Cell and Molecular Biology (University of Bologna, 2007) MSc Molecular Biotechnologies (University of Bologna, 2011) PhD Cell Biology (Royal Veterinary College, University of London, 2016) Research interests include mitochondrial ultrastructure/function relationships, homeostasis signaling pathways, and age-related disease mechanisms. Current projects investigate retrograde signaling pathways in neuronal cells and mitochondria's role in gastrointestinal inflammatory conditions. He leads a UKRI-funded project exploring nucleus-associated mitochondria in cellular signaling (2024–2027). Recent publications analyze mycotoxin impacts on gut health and lung cancer recurrence factors post-surgery. His work combines molecular biology, cellular pathology, and translational medicine approaches.

• Osteology
• Biomechanics
• Bone Remodeling
• +۵ مورد دیگر

Thorsten Schinke is a full-time faculty member and Professor at the Department of Osteology and Biomechanics , University of Hamburg-Eppendorf (UKE). His research focuses on molecular mechanisms of bone remodeling, Wnt/Notch signaling, osteoimmunology, and genetic factors in skeletal disorders. Key Research Themes: Wnt Signaling, Osteoporosis, Osteoimmunology, Skeletal Metastasis, Genetic Bone Diseases, Osteal Macrophages Scientific Contributions: Schinke has led 8 DFG-funded projects (2010-2021) exploring interactions between bone remodeling and disease states. His work includes identifying novel roles for Rsk2, PLS3, and Notch2 in osteosarcoma progression, X-linked osteoporosis, and Hajdu-Cheney syndrome. Using genetically engineered mouse models, he established connections between cytokine signaling (e.g., IL17, S1P), lysosomal dysfunction, and skeletal pathology. Recent Trends: Analysis of 15 recent publications (2017-2021) reveals expertise in in vivo bone modeling, histomorphometry, and cross-disciplinary approaches combining immunology and bone biology. Key subfields include tumor-bone interactions, Wnt-stimulated anabolism, and metabolic regulation of osteoblast/osteoclast balance. Scientific Awards: DFG Project 401122336 (2018-2021) DFG Project 385501541 (2017-2021) DFG Project 278045702 (2015-2019) DFG Project 235869912 (2013-2017) DFG Project 27463524 (2010-2014) Contact: Research conducted at Campus Lehre N55, Martinistrasse 52, Hamburg. Email: fis@uke.de

• Anesthesiology
• Pediatrics
• Perioperative Medicine
• +۳ مورد دیگر

Christian Zöllner is a Professor at the Clinic and Polyclinic for Anesthesiology within the Medical Faculty of the University Medical Center Hamburg-Eppendorf (UKE). His research focuses on pediatric and adult airway management cerebrovascular autoregulation during surgery personalized blood pressure management opioid receptor desensitization in pain . His recent publications highlight advancements in videolaryngoscopy techniques intraoperative neuromonitoring clinical decision support systems , with a strong emphasis on evidence-based perioperative care. He leads projects on µ-opioid receptor mechanisms in inflammatory pain and collaborates within the Neuro-Immune Network Hamburg . His work bridges anesthesiology, neuroscience, and clinical epidemiology.

• Respiratory Medicine
• Pneumology
• Oncology
• +۱۷ مورد دیگر

Jan Siwiec, MD, PhD, is an Assistant Professor and Chair of the Department of Pneumology, Oncology and Allergology at the Faculty of Medicine, Medical University of Lublin. His academic and clinical work centers on respiratory diseases, with a strong focus on asthma, occupational lung disorders, lung cancer, and immunological mechanisms involving interleukin-18 and TH1 cell responses. Institution: Medical University of Lublin School: Faculty of Medicine Department: Department of Pneumology, Oncology and Allergology Position: Assistant Professor and Department Chair Dr. Siwiec’s research spans immunology, genetics, occupational health, and clinical pulmonology. His work investigates how genetic polymorphisms (especially in IL-18), environmental exposures (such as wood and organic dust), and occupational settings influence respiratory disease development and progression. He has contributed significantly to understanding asthma in both general and occupational contexts, lung cancer risk among exposed workers, and immune responses in chronic respiratory conditions. The 15 most recent publications reflect a consistent focus on respiratory health, with strong emphasis on occupational exposures, genetic susceptibility, and inflammatory pathways. Research trends show integration of molecular biology with epidemiological and clinical data, particularly in Polish populations. Key themes include biomarker discovery (e.g., IL-18), public health implications of workplace hazards, and the interplay between infection, immunity, and chronic airway disease. While no formal scientific awards are listed in the provided text, Dr. Siwiec has one recorded achievement and maintains an active research profile with 48 documented publications. His work likely involves collaboration across clinical, research, and public health domains. Dr. Siwiec advises or mentors graduate students in medical and scientific research, though specific names are not listed. His department likely functions as a research and teaching hub within the Faculty of Medicine, engaging in multicenter studies and contributing to national data on respiratory diseases. Research may be supported by institutional or national grants, particularly in occupational health and respiratory epidemiology. The Department of Pneumology, Oncology and Allergology serves as the primary research and clinical team under his leadership, focusing on patient care, education, and investigation into lung diseases. The team appears to collaborate on multi-center projects, especially those involving occupational exposure, genetic studies, and pandemic-related respiratory impacts.

Anthal I.P.M. Smitsمشاهده پروفایل

دانشیار

• Tissue Engineering
• Mechanobiology
• Biomaterials
• +۳ مورد دیگر

Anthal Smits is an Associate Professor at the Department of Biomedical Engineering , Eindhoven University of Technology, leading the ImmunoRegeneration Group . His research focuses on immunomodulation for in situ tissue regeneration, particularly in cardiovascular applications such as heart valves and blood vessels. He is affiliated with the Institute for Complex Molecular Systems (ICMS) and actively contributes to international consortia like NWO Gravitation and NWO Summit . BSc & MSc in Biomedical Engineering, TU/e (2004, 2008) PhD in Biomedical Engineering, TU/e (2014) under Prof. Frank Baaijens His interdisciplinary work bridges tissue engineering , mechanobiology , immunology , and materials science , with recent articles emphasizing biomaterial standardization , calcification mechanisms , and macrophage dynamics . A 2021 ERC Starting Grant supports his macrophage mechanobiology research. Editorial Board: Tissue Engineering Parts A, B, C , Frontiers in Cardiovascular Medicine Professional Affiliations: NBTE , TERMIS EU Chapter , Heart Valve Society

• Cardiovascular Epidemiology
• Nutritional Epidemiology
• Cancer Epidemiology
• +۴ مورد دیگر

Susanna Larsson is an Associate Professor and Senior Researcher at Karolinska Institutet's Institute of Environmental Medicine, where she leads the Cardiovascular and Nutritional Epidemiology Unit. Her work spans multiple disciplines within public health research, with a particular focus on understanding the complex relationships between diet, lifestyle factors, and chronic disease development. Dr. Larsson's research interests primarily center around cardiovascular epidemiology, nutritional epidemiology, and cancer epidemiology, with a strong methodological emphasis on Mendelian randomization techniques. Her work frequently examines how dietary patterns, particularly meat consumption, plant-based diets, and specific nutrients, influence the risk of major chronic diseases including cardiovascular conditions, inflammatory bowel disease, and various cancers. She has made significant contributions to understanding the genetic and environmental determinants of disease through large-scale multinational studies and meta-analyses. Analysis of her extensive publication record (over 100 articles in the past five years) reveals a strong focus on causal inference methods, particularly Mendelian randomization, to untangle complex diet-disease relationships. Her research often bridges nutritional science with genetic epidemiology, examining how genetic predispositions interact with lifestyle factors to influence disease risk. Recent work has particularly emphasized connections between cardiovascular health, metabolic conditions, and gastrointestinal diseases. Dr. Larsson maintains an active research group with several doctoral students and affiliated researchers, including Stephanie Pitt and Shuai Yuan. Her collaborative approach is evident in the numerous multinational studies she participates in, often involving data from multiple countries across Europe, Asia, Australia, and North America. Her laboratory work focuses on the Cardiovascular and Nutritional Epidemiology Unit, which conducts population-based research examining how dietary patterns, lifestyle factors, and genetic predispositions influence chronic disease development and progression. The unit employs advanced epidemiological methods, including large-scale cohort studies, meta-analyses, and genetic epidemiology approaches to investigate causal relationships in public health.

• Cell Death
• Ferroptosis
• Redox Signaling
• +۵ مورد دیگر

Professor Marcus Conrad serves as Director of the Institute of Metabolism and Cell Death at Helmholtz Munich and holds the Chair of Translational Redox Biology at the Technical University of Munich (TUM) since 2024. His research bridges basic science and translation through the identification and pharmacological targeting of key nodes in cell death and necro-inflammatory processes. Conrad earned his PhD from Helmholtz Zentrum München and Ludwig-Maximilians-University Munich with highest honors (summa cum laude), focusing on selenoproteins in transgenic mice. His academic journey includes research positions at Karolinska Institute, Yamagata University, and leadership roles at Helmholtz Zentrum München before his current directorship. Conrad's research primarily focuses on ferroptosis, a regulated cell death pathway dependent on iron and lipid peroxidation. His work explores how understanding these molecular mechanisms can prevent neurodegenerative diseases and combat cancer. He has made significant contributions to understanding the role of GPX4, FSP1, and other key regulators in ferroptosis, with implications for drug discovery and therapeutic interventions. His publication record shows a strong focus on ferroptosis mechanisms, with recent work exploring novel ferroptosis suppressors, metabolic connections to cell death pathways, and implications for diseases including cancer, neurodegeneration, and kidney disease. His research demonstrates the growing recognition of ferroptosis as a critical pathway with therapeutic potential across multiple disease areas. Galenus-von-Pergamon-Price (2024) European Cell Death Organisation (ECDO) Honorary Award 2024 Multiple ISI Highly Cited Awards (2020-2024) ERC Advanced Grant "IRONDEATH" (2020) m4 Awards for Personalized Medicine (2012, 2017) Conrad has secured significant research funding including an ERC Advanced Grant and coordinates the Deutsche Forschungsgemeinschaft Priority Programme on Ferroptosis (2021-2026) involving 25 centers. He co-founded ROSCUE THERAPEUTICS GmbH in 2020, translating his research into potential therapeutics. Conrad actively mentors researchers through his institute and has organized multiple international conferences on ferroptosis, including EMBO workshops and Cold Spring Harbor Asia conferences. His institute at Helmholtz Munich serves as a hub for ferroptosis research, bringing together experts in redox biology, cell death mechanisms, and translational medicine. Conrad's leadership has positioned his team at the forefront of understanding how regulated cell death pathways can be targeted for therapeutic benefit in multiple disease contexts.

Michael Drozdمشاهده پروفایل

مدرس

• Cardiology
• Cardiometabolic Disease
• Infection and Immunity
• +۷ مورد دیگر

Dr. Michael Drozd is an Academic Clinical Lecturer in the School of Medicine at the University of Leeds, part of the Faculty of Medicine and Health. He is affiliated with the Leeds Institute of Cardiovascular and Metabolic Medicine, where he conducts translational research in cardiology with a focus on cardiometabolic diseases and infection. His work bridges clinical practice and scientific investigation, particularly in understanding how metabolic conditions like diabetes influence cardiovascular and infectious disease outcomes. Position: Academic Clinical Lecturer Institution: University of Leeds School: School of Medicine Research Institute: Leeds Institute of Cardiovascular and Metabolic Medicine Email: M.Drozd@leeds.ac.uk Dr. Drozd holds a BSc, MBChB (with honors), and PhD. He is a member of the Royal College of Physicians (MRCP) and the European Society of Cardiology (FESC), reflecting his clinical and academic credentials. His research interests center on cardiometabolic disease and infection , with a strong emphasis on translational approaches. Key areas include: Mechanisms linking diabetes, obesity, and cardiovascular disease Infection-related mortality in metabolic disorders Endothelial signaling in vascular dysfunction Biomarker discovery in heart failure Hypoxia and innate immune training Inflammation as a driver of cardiovascular risk His recent publications, spanning from 2017 to 2025, demonstrate a consistent output in high-impact journals such as Diabetes Care , Cardiovascular Research , The Lancet , and J Infect . These works often utilize large cohort data (e.g., UK Biobank) and molecular techniques to explore causal relationships and novel pathways. A recurring theme is the intersection of metabolic health, immune response, and cardiovascular outcomes. Dr. Drozd is actively involved in medical education, supervising MBChB students and academic foundation doctors, and delivering cardiovascular teaching across multiple years of the medical curriculum. He is also passionate about widening participation in medicine, contributing to equity in medical education. His scientific contributions include: Investigating plasma MERTK as a causal biomarker for infection mortality Identifying novel transcriptomic biomarkers (Erbb3, Hspa2) in diabetic heart failure Elucidating IGF-1 signaling in endothelial barrier function and atherogenesis Mapping comorbidity trajectories in heart failure Exploring mentorship challenges in cardiology training Dr. Drozd collaborates extensively with leading researchers such as Professor Mark T. Kearney, Dr. Ryan M. Cubbon, and Professor Stephen B. Wheatcroft. He is not listed as retired, deceased, or former staff, and there is no indication of part-time status. His ongoing research and teaching activities confirm his active role in academic medicine.

• Muscle Metabolism
• Insulin Resistance
• Diabetes Research
• +۱۱ مورد دیگر

Dr. Richard Mackenzie is a Reader in Insulin Resistance & Metabolism at the School of Life and Health Sciences, University of Roehampton , where he also serves as Research Director for the Sport & Exercise Science Research Group. He previously held a Senior Lecturer position at the University of Westminster (2008-2015) and was a Research Physiologist at the University of Brighton (2005-2008). His research focuses on metabolic regulation in health and disease states, particularly type 2 diabetes and elite athlete physiology. Dr. Mackenzie's work explores: Muscle metabolism in health, obesity, and diabetes Role of obesity in insulin resistance and metabolic disease Hematological and muscular adaptations to acute hypoxia Akt/PKB inhibition via IP6K1 and IP7 in insulin signaling Myostatin signaling and skeletal muscle protein turnover His peer-reviewed publications examine topics ranging from hypoxia-induced metabolic changes to dietary interventions for glucose homeostasis. Dr. Mackenzie also engages in media appearances (BBC Radio 4, Horizon documentaries) and consultancy work for metabolic device development (e.g., Mediwise glucose-monitoring technology).